| Serial Number | 97855612 |
| Word Mark | HEPNET |
| Filing Date | Friday, March 24, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, November 26, 2024 |
| Registration Number | 7575493 |
| Registration Date | Tuesday, November 26, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 12, 2024 |
| Goods and Services | Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid |
| Goods and Services | Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery |
| Goods and Services | Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation |
| Goods and Services | Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 16, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 16, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus. |
| US Class Codes | 021, 023, 026, 036, 038 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 16, 2023 |
| Primary Code | 009 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 16, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | E-Therapeutics Plc |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | London W26BD GB |
| Party Name | E-Therapeutics Plc |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | London W26BD GB |
| Party Name | E-Therapeutics Plc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | London W26BD GB |
| Event Date | Event Description |
| Tuesday, March 28, 2023 | NEW APPLICATION ENTERED |
| Sunday, April 16, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, April 25, 2023 | ASSIGNED TO EXAMINER |
| Thursday, April 27, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, April 27, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, April 27, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 18, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, May 18, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, May 18, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, July 31, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, December 26, 2023 | ASSIGNED TO LIE |
| Tuesday, December 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, December 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 30, 2024 | PRIORITY ACTION WRITTEN |
| Tuesday, January 30, 2024 | PRIORITY ACTION E-MAILED |
| Tuesday, January 30, 2024 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Tuesday, January 30, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, January 30, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, January 30, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 21, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, February 2, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 21, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 12, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 7, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, March 12, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Monday, November 4, 2024 | NOTICE OF ALLOWANCE CANCELLED |
| Monday, November 4, 2024 | TEAS DELETE 1(B) BASIS RECEIVED |
| Tuesday, November 5, 2024 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| Tuesday, November 26, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, November 26, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |